<DOC>
	<DOCNO>NCT00025077</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery radiation therapy may shrink tumor remove surgery radiation therapy . Peripheral stem cell transplant may able replace immune cell destroy chemotherapy radiation therapy allow doctor give high dos chemotherapy . PURPOSE : This phase II trial study well combination chemotherapy follow surgery radiation therapy peripheral stem cell transplant work treat patient recurrent medulloblastoma primitive neuroectodermal pineal tumor .</brief_summary>
	<brief_title>Combination Chemotherapy , Surgery Radiation Therapy , Peripheral Stem Cell Transplant Treating Patients With Recurrent Medulloblastoma Primitive Neuroectodermal Pineal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility cyclophosphamide surgical resection radiotherapy follow thiotepa , carboplatin , autologous peripheral blood stem cell rescue patient recurrent medulloblastoma supratentorial neuroectodermal pineal tumor . - Determine acute chronic toxicity regimen patient . - Determine progression-free overall survival patient treat regimen . OUTLINE : This multicenter study . - Cytoreductive Phase : Patients receive cyclophosphamide IV 1 hour day 1 2 filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 7 continue blood count recover . Treatment repeats discontinuation G-CSF 2-4 course . Peripheral blood stem cell ( PBSC ) harvest course cyclophosphamide . Patients undergo surgical resection radiotherapy completion chemotherapy . Patients achieve complete response proceed myeloablative therapy . - Myeloablative Phase : Patients receive thiotepa IV 3 hour day 1-3 . Autologous PBSC reinfused day 5 patient receive G-CSF SC daily begin day 10 continue blood count recover . Beginning 2 day completion G-CSF , patient receive carboplatin IV 1 hour day 1-3 . Autologous PBSC reinfused day 5 patient receive G-CSF SC daily begin day 10 continue blood count recover . Patients follow 1 , 3 , 6 , 12 month . PROJECTED ACCRUAL : Approximately 50 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent medulloblastoma supratentorial primitive neuroectodermal pineal tumor Nodular/desmoplastic medulloblastoma Medullomyoblastoma Melanotic medulloblastoma Ependymoblastoma Pinealoblastoma Received prior craniospinal radiotherapy OR Relapse site prior localize radiotherapy ( e.g. , relapse `` baby brain '' protocol ) PATIENT CHARACTERISTICS : Age : Under 21 Performance status : Lansky 40100 % age 116 year Karnofsky 40100 % age 16 year Life expectancy : At least 8 week Hematopoietic : Neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le upper limit normal ( ULN ) AST le 2 time ULN Renal : Glomerular filtration rate least 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
</DOC>